For the second quarter of 2026, analysts expect Novo Nordisk to report consensus revenue of $11.27 billion and EPS of $0.82, with the current stock price of $47.08 trading well below the average analyst target of $65.56.
Investors are primarily focused on the commercial performance of the newly launched oral Wegovy pill as the company navigates a challenging trough year.
Total revenue is projected to contract by 3.5% year-over-year due to heavy pricing pressure in the U.S. and the recent failure of the late-stage ZEUS clinical trial. These headwinds have shifted investor attention toward management’s ability to defend its cardiometabolic market share against intensifying competition from Eli Lilly's weight-loss portfolio.